Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | UGCG | Q16739 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29907563 | 0.86 | TSHR (0.45) | MAPTUGCG | |
| SCHEMBL29601829 | 0.85 | UGCG (0.59) | UGCG | |
| SCHEMBL29907424 | 0.85 | UGCG (0.51) | SMN1; SMN2MAPTUGCG | |
| SCHEMBL29907402 | 0.84 | ALDH1A1 (0.47) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL29907339 | 0.83 | UGCG (0.43) | KMT2AMEN1NR3C1UGCG | |
| SCHEMBL29907624 | 0.82 | UGCG (0.44) | KMT2AMEN1SMN1; SMN2RXFP1MAPT | |
| SCHEMBL29907665 | 0.82 | UGCG (0.47) | SMN1; SMN2RXFP1MAPTUGCG | |
| SCHEMBL29907650 | 0.80 | TSHR (0.41) | KMT2AALDH1A1TP53UGCGKDM4E | |
| SCHEMBL29602191 | 0.78 | UGCG (0.46) | UGCG | |
| SCHEMBL29907363 | 0.77 | SCN9A (0.46) | KMT2AMEN1SMN1; SMN2UGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-15 | — | — | US | disclosed |
| EP-4005637-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | KMT2A 540/4885MEN1 2070/4885SMN1; SMN2 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.